Pulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of “Moderate Buy” by Analysts

Pulmonx Co. (NASDAQ:LUNG) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $12.75.

Several research firms have recently commented on LUNG. Wells Fargo & Company reduced their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Citigroup restated a “neutral” rating and issued a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th.

Insiders Place Their Bets

In other Pulmonx news, insider Geoffrey Beran Rose sold 5,779 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the completion of the sale, the insider now owns 285,278 shares in the company, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel David Aaron Lehman sold 22,355 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.65, for a total value of $171,015.75. Following the completion of the sale, the general counsel now owns 175,496 shares of the company’s stock, valued at $1,342,544.40. The trade was a 11.30 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 127,986 shares of company stock worth $986,673. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LUNG. 272 Capital LP bought a new position in shares of Pulmonx during the 3rd quarter valued at about $25,000. BNP Paribas Financial Markets bought a new position in shares of Pulmonx during the 4th quarter valued at about $43,000. R Squared Ltd bought a new position in shares of Pulmonx during the 4th quarter valued at about $46,000. ProShare Advisors LLC bought a new position in shares of Pulmonx during the 4th quarter valued at about $72,000. Finally, Stifel Financial Corp bought a new position in shares of Pulmonx during the 4th quarter valued at about $81,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Price Performance

Shares of LUNG opened at $7.48 on Monday. The firm has a market cap of $297.67 million, a PE ratio of -5.19 and a beta of 0.50. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a fifty day simple moving average of $6.95 and a two-hundred day simple moving average of $6.94. Pulmonx has a 1-year low of $5.46 and a 1-year high of $10.01.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, equities analysts anticipate that Pulmonx will post -1.55 EPS for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.